We have completed a third-party allotment of capital. While aiming to increase the number of N-NOSE tests and improve the consultation rate, we will promote our business with the immediate goal of putting the next-generation cancer type specific tests into practical use.
The international biomedical journal Biomedicines has just published a peer-reviewed review article* on data showing the effectiveness of N-NOSE . . .
2024.11.15At the Excellence in Oncology Care (EIOC) 2024 conference held in Dubai from October 11 (Fri.) to 13 (Sun.), 2024, our Shonan R&D Center Res . . .
2024.10.25We, HIROTSU BIO SCIENCE Inc., participated in the Excellence in Oncology Care (EIOC) 2024 conference that was held in Dubai from October 11th (F . . .
2024.10.17